DBV Technologies Joins Euronext Tech Leaders Index as of June 22
DBV Technologies announced on Tuesday its inclusion in the Euronext Tech Leaders index, effective since June 22. This recognition positions the French biotech alongside selected European companies known for their innovation and growth trajectory.
An Integration Rewarding the Biotech's Scientific Approach
DBV Technologies has now joined the Euronext Tech Leaders index, which includes over 100 companies listed on the European Euronext markets (Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo, and Paris). This index comprises companies recognized for their innovation, growth trajectory, and contribution to the European technological ecosystem, in sectors such as software, biotechnology, fintech, clean technologies, and semiconductors. Daniel Tassé, CEO of DBV Technologies, stated, 'We are honored to be part of the Euronext Tech Leaders index and to be recognized alongside some of the most innovative companies in Europe.'
Viaskin Peanut at the Heart of Therapeutic Strategy
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The French biotech is focusing its efforts on the development of the Viaskin Peanut patch, an epicutaneous immunotherapy (EPIT) treatment for children allergic to peanuts. This patch is designed to deliver micrograms of a biologically active compound through intact skin, aiming to retrain the immune system to desensitize to the allergen. DBV Technologies is currently conducting clinical studies with the Viaskin Peanut patch in young children (ages 1 to 3) and children (ages 4 to 7) allergic to peanuts. The group emphasizes that this inclusion reflects the strength of its scientific approach and the significant progress made in the development of this drug candidate.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
